Share Name Share Symbol Market Type Share ISIN Share Description
AstraZeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.50p -0.41% 4,979.00p 4,978.50p 4,980.00p 5,001.00p 4,957.50p 4,991.00p 362,441 14:31:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,627.4 2,876.5 224.3 23.9 63,016.25

AstraZeneca Share Discussion Threads

Showing 10426 to 10446 of 10450 messages
Chat Pages: 418  417  416  415  414  413  412  411  410  409  408  407  Older
DateSubjectAuthorDiscuss
11/10/2017
12:49
I guess we will be getting an apology here from Buywell. I have never seen him make a correct call. Of these over the last month Barc up slightly RBS up about 15% from 230 to 270 LLoy up slightly BP up 10% 450 to 490 AZN up 10% 4700-5200 GNK down slightly. FTSE at 7500 vs prediction of 6750 Listen to him at your financial cost. FWIW I continue to hold here. buywell317 Sep '17 - 19:26 - 2018 of 2027 0 0 buywell FTSE 100 alert issued 7100 coming next week followed by 6750 within 4 weeks as of today Reasons why posted on BARC AZN chart IMO like that of BARC in now starting another leg down as it is on every chart I have looked at this evening BARC ,RBS ,LLOY ,BP. , SIA , GNK and now AZN FTSE 100 at 6750 should equate to a retest of 4380p AZN IMO $29 in the US dyor
dr biotech
08/10/2017
11:51
[...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance | Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment
cool druid
07/10/2017
09:12
I brought a few months ago when it went down am surprised so few posts for this stock Doing well so far not sure if will get back to 54 but happy so far with the gain
mrthomas
03/10/2017
12:51
Dr B , no Not listening , just always interested in what chartists will say following a suggestion that appears not to be unfolding , and why that should be so . Noting particularly no reply .
holts
03/10/2017
11:26
Ironhorse I sincerely hope and expect that your petition fails to garner sufficient support and even if it does, then our elected representatives will consign it to the dustbin of history. Two wrongs do not make a right.
toffeeman
02/10/2017
19:34
Listening to buywell will cost you a lot of money. Takes a lot of skill to say sell at exactly the lowest point. He's done that multiple times with others buywell317 Sep '17 - 19:26 - 2018 of 2021 0 0 buywell FTSE 100 alert issued 7100 coming next week followed by 6750 within 4 weeks as of today Reasons why posted on BARC AZN chart IMO like that of BARC in now starting another leg down as it is on every chart I have looked at this evening BARC ,RBS ,LLOY ,BP. , SIA , GNK and now AZN FTSE 100 at 6750 should equate to a retest of 4380p AZN IMO $29 in the US dyor
dr biotech
02/10/2017
18:43
Buywell3 , i dont do charts particularly , has the view changed or are you still looking at the same scenario ?
holts
22/9/2017
13:28
Dividends and growth if you are willing to hold long enough. Not a bad combination.
city chappy
18/9/2017
10:43
I think its GS had a negative note on Astra.
montyhedge
17/9/2017
18:26
buywell FTSE 100 alert issued 7100 coming next week followed by 6750 within 4 weeks as of today Reasons why posted on BARC AZN chart IMO like that of BARC in now starting another leg down as it is on every chart I have looked at this evening BARC ,RBS ,LLOY ,BP. , SIA , GNK and now AZN FTSE 100 at 6750 should equate to a retest of 4380p AZN IMO $29 in the US dyor
buywell3
07/9/2017
18:21
Heading towards the very big gap
holts
07/9/2017
10:56
the new asthma drug looks promising.
careful
03/9/2017
16:53
can expect a pullback from a chart point of view, if current pattern is to be continued, North Korea likely to influence markets tomorrow, expecting 4480 to give support, but external factors can blow any charts out the window
nocky44
03/9/2017
08:13
Alp - Don't always agree with you but that post is bang on the money.
ianood
02/9/2017
10:59
Nothing new here. IP has always been an issue. Generics will nearly always appear once big sellers go off patent. The strength of the IP protection has always been important. No lessons to be learnt.
alphorn
01/9/2017
11:29
Re GSK or AZN Why not try both?
marksp2011
11/8/2017
09:48
Hmm. This is the first post of the trading week and I have nothing to say.
grahamite2
05/8/2017
06:32
Neurological diseases like Alzheimers' are being wrongly diagnosed They are forms of CJD caused by prions ..... it is a MASSIVE cover up read this hTTps://www.thetyee.ca/Documents/2017/06/24/Risk-Advisory-Opinion-CWD-2017.pdf then this hTTp://crossbowcommunications.com/wildlife-contracting-brain-disease-from-biosolids/
buywell3
02/8/2017
14:00
M, would be interesting. GSK X for 19 pence tomorrow from memory. Agree with Woodford's comment on liberal amounts of full valuations currently. I'm often too cautious though. Edit, GSK XD is next Thursday.
essentialinvestor
02/8/2017
13:03
Happy to compare notes in 12-18mnths romeike Your GSK against my RB. and AZN equivalent mix.
minerve
02/8/2017
12:41
Rubbish, there is only one reason to hold AZ now over GSK and that is on the hope it will get bought out. May government will never see AZ sold off, just look at recent statements on this exact point. Current CEO should be begging investors for forgiveness for poo-pooing an AMAZING offer from Pfizer, shamelessly hyping AZ pipeline into the stratosphere. On the other hand, having seen Emma Walmsley at GSK in action, very impressive... If I want risk I'll go biotech thanks, better returns than anything AZ offers. Good luck all.
romeike
Chat Pages: 418  417  416  415  414  413  412  411  410  409  408  407  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171124 14:46:43